Compare Moderna, Inc. (MRNA) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Verizon Communications Inc — how do they compare? Moderna, Inc. trades at $136.47 (market cap $56.02B), while Verizon Communications Inc trades at $50.01 (market cap $209.44B). The key difference: Verizon Communications Inc is far larger — about 3.7× Moderna, Inc.'s market cap, and Verizon Communications Inc pays a 5.61% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | VZ | |
|---|---|---|
Market Cap | $56.02B | $209.44B |
Sector | Health | Media |
52-Week High | $174.38 | $51.38 |
52-Week Low | $22.36 | $38.40 |
Enterprise Value | $52.17B | $396.15B |
Volume | — | 22,584,735 |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Verizon (VZ) trades at $50.41, up 0.54% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock offers a 5%+ dividend yield, supported by strong cash flow and a P/E of 13.13. Recent news highlights growth in broadband and AI infrastructure, including a multi-billion dollar fiber deal with Corning.
Outlook is positive with cost discipline and shareholder returns, but risks include high debt and competitive pressures. Analysts are mixed with a $49.69 consensus target, slightly below current price, indicating cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
